Cannabis and Δ9-tetrahydrocannabinol (THC) for weight loss?

Medical Hypotheses

Volumn 80, Issue 5, 2013, Pages 564-567

  Le Foll, Bernard ^a,b   Trigo, Jose M ^a   Sharkey, Keith A ^c   Strat, Yann Le ^a,d,e,f  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d CENTRE DE PSYCHIATRIE ET NEUROSCIENCES   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f HÔPITAL LOUIS MOURIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABIS; DRONABINOL; NABIXIMOLS;

ANALGESIC ACTIVITY; APPETITE; ARTICLE; BODY MASS; CANCER PAIN; CANNABIS ADDICTION; CANNABIS SMOKING; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; HUMAN; NEUROPATHIC PAIN; NONHUMAN; OBESITY; PREVALENCE; WEIGHT GAIN; WEIGHT REDUCTION;

CANNABIS; EVIDENCE-BASED MEDICINE; HUMANS; MARIJUANA SMOKING; OBESITY; PLANT EXTRACTS; TETRAHYDROCANNABINOL; TREATMENT OUTCOME; WEIGHT LOSS;

CANNABIS; NICOTIANA TABACUM;

EID: 84875622140     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.01.019     Document Type: Article

References (57)

1. Available from: http://www.who.int/mediacentre/factsheets/fs311/en/.
2. Le Foll B., Gorelick D.A., Goldberg S.R. The future of endocannabinoid-oriented clinical research after CB1 antagonists. Psychopharmacology (Berl) 2009, 205(1):171-174.
3. Di Marzo V., Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005, 8(5):585-589.
4. Solinas M., Goldberg S.R. Motivational effects of cannabinoids and opioids on food reinforcement depend on simultaneous activation of cannabinoid and opioid systems. Neuropsychopharmacology 2005, 30(11):2035-2045.
5. Beal J., Flynn N. AIDS-associated anorexia. J Phys Assoc AIDS Care 1995, 2(1):19-22.
6. Dejesus E., et al. Use of dronabinol improves appetite and reverses weight loss in HIV/AIDS-infected patients. J Int Assoc Phys AIDS Care (Chic) 2007, 6(2):95-100.
7. Heal D.J., Gosden J., Smith S.L. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. Br J Clin Pharmacol 2009, 68(6):861-874.
8. Bello N.T., et al. Dietary conditions and highly palatable food access alter rat cannabinoid receptor expression and binding density. Physiol Behav 2012, 105(3):720-726.
9. Matias I., et al. Endocannabinoids measurement in human saliva as potential biomarker of obesity. PLoS One 2012, 7(7):e42399.
10. Monteleone P., et al. Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology 2005, 30(6):1216-1221.
11. Warren M., Frost-Pineda K., Gold M. Body mass index and marijuana use. J Addict Dis 2005, 24(3):95-100.
12. Farhat T., Iannotti R.J., Simons-Morton B.G. Overweight, obesity, youth, and health-risk behaviors. Am J Prev Med 2010, 38(3):258-267.
13. Rodondi N., et al. Marijuana use, diet, body mass index, and cardiovascular risk factors (from the CARDIA study). Am J Cardiol 2006, 98(4):478-484.
14. Le Strat Y., Le Foll B. Obesity and cannabis use: results from 2 representative national surveys. Am J Epidemiol 2011, 174(8):929-933.
15. Rajavashisth T.B., et al. Decreased prevalence of diabetes in marijuana users: cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) III. BMJ Open 2012, 2:e000494.
16. Jarbe T.U., DiPatrizio N.V. Delta9-THC induced hyperphagia and tolerance assessment: interactions between the CB1 receptor agonist delta9-THC and the CB1 receptor antagonist SR-141716 (rimonabant) in rats. Behav Pharmacol 2005, 16(5-6):373-380.
17. Williams C.M., Rogers P.J., Kirkham T.C. Hyperphagia in pre-fed rats following oral delta9-THC. Physiol Behav 1998, 65(2):343-346.
18. Barbano M.F., et al. Delta-9-tetrahydrocannabinol enhances food reinforcement in a mouse operant conflict test. Psychopharmacology (Berl) 2009, 205(3):475-487.
19. Rahminiwati M., Nishimura M. Effects of delta 9-tetrahydrocannabinol and diazepam on feeding behavior in mice. J Vet Med Sci 1999, 61(4):351-355.
20. Vaupel D.B., Morton E.C. Anorexia and hyperphagia produced by five pharmacologic classes of hallucinogens. Pharmacol Biochem Behav 1982, 17(3):539-545.
21. NTP Toxicology and Carcinogenesis Studies of 1-Trans-Delta(9)-Tetrahydrocannabinol (CAS No. 1972-08-3) in F344 Rats and B6C3F1 Mice (Gavage Studies). Natl Toxicol Program Tech Rep Ser, 1996;446:1-317.
22. Molina P.E., et al. Cannabinoid administration attenuates the progression of simian immunodeficiency virus. AIDS Res Hum Retroviruses 2011, 27(6):585-592.
23. Winsauer P.J., et al. Tolerance to chronic delta-9-tetrahydrocannabinol (delta(9)-THC) in rhesus macaques infected with simian immunodeficiency virus. Exp Clin Psychopharmacol 2011, 19(2):154-172.
24. Klein C., et al. Cannabidiol potentiates delta(9)-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats. Psychopharmacology (Berl) 2011, 218(2):443-457.
25. Shen E.Y., Ali S.F., Meyer J.S. Chronic administration of THC prevents the behavioral effects of intermittent adolescent MDMA administration and attenuates MDMA-induced hyperthermia and neurotoxicity in rats. Neuropharmacology 2011, 61(8):1183-1192.
26. Levendal R.A., et al. Cannabis exposure associated with weight reduction and beta-cell protection in an obese rat model. Phytomedicine 2012, 19(7):575-582.
27. Sativex®Product Monograph. Available from: http://www.ukcia.org/research/SativexMonograph.pdf.
28. Murray J.E., Bevins R.A. Cannabinoid conditioned reward and aversion: behavioral and neural processes. ACS Chem Neurosci 2010, 1(4):265-278.
29. Di Marzo V., et al. Changes in plasma endocannabinoid levels in viscerally obese men following a 1year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors. Diabetologia 2009, 52(2):213-217.
30. Pertwee R.G. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 2008, 153(2):199-215.
31. Cote M., et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes (Lond) 2007, 31(4):692-699.
32. Bluher M., et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006, 55(11):3053-3060.
33. Matias I., et al. Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: effect of high fat diets. Mol Cell Endocrinol 2008, 286(1-2 Suppl. 1):p-78.
34. Borrelli F., Izzo A.A. Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance. Best Pract Res Clin Endocrinol Metab 2009, 23(1):33-49.
35. Despres J.P., Lemieux I., Almeras N. Contribution of CB1 blockade to the management of high-risk abdominal obesity. Int J Obes (Lond) 2006, 30(Suppl. 1):S44-S52.
36. Clapper J.R., Mangieri R.A., Piomelli D. The endocannabinoid system as a target for the treatment of cannabis dependence. Neuropharmacology 2009, 56(Suppl. 1):235-243.
37. Sim-Selley L.J. Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit Rev Neurobiol 2003, 15(2):91-119.
38. Kirkham T.C. Endocannabinoids in the regulation of appetite and body weight. Behav Pharmacol 2005, 16(5-6):297-313.
39. Cluny N.L., et al. The neutral cannabinoid CB(1) receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat. Pharmacol Biochem Behav 2011, 97(3):537-543.
40. Fride E., et al. Inhibition of milk ingestion and growth after administration of a neutral cannabinoid CB1 receptor antagonist on the first postnatal day in the mouse. Pediatr Res 2007, 62(5):533-536.
41. Wiley J.L., et al. Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist. Eur J Pharmacol 2011, 651(1-3):96-105.
42. McLaughlin P.J., et al. The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats. Behav Pharmacol 2003, 14(8):583-588.
43. Di Marzo V. Available from: http://www.cannabis-med.org/meeting/Bonn2011/abstractbook.pdf.
44. Gomez R., et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 2002, 22(21):9612-9617.
45. Alonso M., et al. Anti-obesity efficacy of LH-21, a cannabinoid CB(1) receptor antagonist with poor brain penetration, in diet-induced obese rats. Br J Pharmacol 2012, 165(7):2274-2291.
46. Pavon F.J., et al. Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole - LH 21. Neuropharmacology 2006, 51(2):358-366.
47. Pavon F.J., et al. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist in Zucker rats. J Neuroendocrinol 2008, 20(Suppl. 1):116-123.
48. Cluny N.L., et al. A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. Br J Pharmacol 2010, 161(3):629-642.
49. LoVerme J., et al. Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice. Bioorg Med Chem Lett 2009, 19(3):639-643.
50. Randall P.A., et al. The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behavior. Pharmacol Biochem Behav 2010, 97(1):179-184.
51. Tam J., et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest 2010, 120(8):2953-2966.
52. Guagnini F., et al. Tolerance to cannabinoid response on the myenteric plexus of guinea-pig ileum and human small intestinal strips. Br J Pharmacol 2006, 148(8):1165-1173.
53. Anderson P.F., et al. Tolerance to the effect of delta9-tetrahydrocannabinol in mice on intestinal motility, temperature and locomotor activity. Psychopharmacologia 1975, 43(1):31-36.
54. Fride E. Anandamides: tolerance and cross-tolerance to delta 9-tetrahydrocannabinol. Brain Res 1995, 697(1-2):83-90.
55. Izzo A.A., Sharkey K.A. Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther 2010, 126(1):21-38.
56. Flegal K.M., et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012, 307(5):491-497.
57. Flegal K.M., et al. Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA 2007, 298(17):2028-2037.